Balance Sheet

Accounts Payables Accumulated Expenses Assets Capital Leases Cash & Current Investments Cash & Equivalents Common Equity Convertible Debt Curent Deferred Tax Liability Current Assets Current Deferred Revenue Current Deferred Tax Assets Current Leases Current Taxes Goodwill Goodwill & Intangibles Intangibles Inventory Liabilities and Shareholders Equity Liabilities from Discontinued Operations Long-Term Deferred Tax Long-Term Investments Minority Interest Non-Current Assets Non-Current Debt Non-Current Deferred Tax Liability Non-Current Deffered Revenue Notes Payables Operating Leases Other Accumulated Expenses Other Non-Current Assets Other Non-Current Liabilities Payables Preferred Stock Liabilities Prepaid Assets Property, Plant & Equipment (Net)Receivables Retained Earnings Shareholder's Equity Short term Debt Short-term Investments Total Current Liabilities Total Debt Total Liabilities Total Non-Current Liabilities Treasury Shares Work In Process

Daily Values

Growth Metrics

Others

Ligand Pharmaceuticals (LGND) Raw Materials (2023 - 2024)

Ligand Pharmaceuticals' Raw Materials history spans 2 years, with the latest figure at $603000.0 for Q4 2024.

For Q4 2024, Raw Materials rose 43.57% year-over-year to $603000.0; the TTM value through Dec 2024 reached $603000.0, up 43.57%, while the annual FY2024 figure was $603000.0, 43.57% up from the prior year.
Raw Materials for Q4 2024 was $603000.0 at Ligand Pharmaceuticals, down from $2.5 million in the prior quarter.
Across five years, Raw Materials topped out at $2.5 million in Q3 2024 and bottomed at $420000.0 in Q4 2023.